These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1641 related items for PubMed ID: 29123013

  • 1. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.
    Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
    [Abstract] [Full Text] [Related]

  • 3. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.
    Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
    Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [Abstract] [Full Text] [Related]

  • 7. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.
    Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl G.
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1656-1662. PubMed ID: 28646463
    [Abstract] [Full Text] [Related]

  • 8. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.
    Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730
    [Abstract] [Full Text] [Related]

  • 9. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May 02; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

  • 10. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy.
    Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V.
    Eur J Nucl Med Mol Imaging; 2020 Sep 02; 47(10):2339-2347. PubMed ID: 32157427
    [Abstract] [Full Text] [Related]

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep 02; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 12. Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.
    Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM.
    J Nucl Med; 2019 Jun 02; 60(6):794-800. PubMed ID: 30442757
    [Abstract] [Full Text] [Related]

  • 13. Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL.
    Kranzbühler B, Müller J, Becker AS, Garcia Schüler HI, Muehlematter U, Fankhauser CD, Kedzia S, Guckenberger M, Kaufmann PA, Eberli D, Burger IA.
    J Nucl Med; 2020 Feb 02; 61(2):194-201. PubMed ID: 31375566
    [Abstract] [Full Text] [Related]

  • 14. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B, Farag M, Liodakis P, Angus D, Lim Joon D, Bolton D.
    BJU Int; 2021 May 02; 127 Suppl 1():23-29. PubMed ID: 33973332
    [Abstract] [Full Text] [Related]

  • 15. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
    Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
    Strahlenther Onkol; 2018 Apr 02; 194(4):303-310. PubMed ID: 29134231
    [Abstract] [Full Text] [Related]

  • 16. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 17. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 10; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.
    Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.
    Ann Nucl Med; 2019 May 10; 33(5):326-332. PubMed ID: 30778860
    [Abstract] [Full Text] [Related]

  • 19. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
    Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.
    Lancet Oncol; 2019 Sep 10; 20(9):1286-1294. PubMed ID: 31375469
    [Abstract] [Full Text] [Related]

  • 20. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.
    Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W.
    J Nucl Med; 2020 Oct 10; 61(10):1484-1490. PubMed ID: 32060214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.